SCHEMBL3397035

SCHEMBL3397035

COc1cc(CBr)cc(OC)c1C

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CA2 P00918 1/20 0.43
PTGS2 P35354 1/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
ALDH1A1 P00352 2/20 0.39
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
HTR2B P41595 1/20 0.39
ATM Q13315 2/20 0.38
KDM4E B2RXH2 1/20 0.38
ACHE P22303 2/20 0.37
PPARG P37231 1/20 0.36
PPARD Q03181 1/20 0.36
PPARA Q07869 1/20 0.36
POLB P06746 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP19A1 P11511 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17447209 0.89 CA2 (0.39) CA2PTGS2MEN1KMT2ARXFP1
SCHEMBL89710 0.83 L3MBTL1 (0.39) MEN1KMT2ARXFP1ALDH1A1CYP3A4
SCHEMBL13754262 0.80 PTGS2 (0.67) CA2PTGS2MEN1KMT2ARXFP1
SCHEMBL722969 0.80 PTGS2 (0.67) PTGS2MEN1KMT2AALDH1A1HTR2A
SCHEMBL30041126 0.80 CA2 (0.43) CA2PTGS2ALDH1A1HTR2AHTR2C
SCHEMBL13347320 0.78 CA2 (0.41) CA2PTGS2MEN1KMT2ARXFP1
SCHEMBL3394143 0.78 MEN1 (0.46) CA2PTGS2MEN1KMT2ARXFP1
Phosphine SCHEMBL9707943 0.78 PTGS2 (0.64) PTGS2MEN1KMT2AALDH1A1HTR2A
SCHEMBL13145025 0.78 CA2 (0.41) CA2PTGS2MEN1KMT2ARXFP1
SCHEMBL6171344 0.78 CA2 (0.47) CA2MEN1KMT2AALDH1A1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2145888-A1 Deazapurine derivatives as HSP90-Inhibitors Conforma Therapeutics Corporation (US) 2010-01-20 EP disclosed
US-20070185064-A1 2-Aminopurine Analogs Having HSP90-Inhibiting Activity CONFORMA THERAPEUTICS CORPORATION (US) 2007-08-09 US disclosed
US-7138401-B2 2-aminopurine analogs having HSP90-inhibiting activity CONFORMA THERAPEUTICS CORPORATION (US) 2006-11-21 US disclosed
EP-1670802-A2 NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS Conforma Therapeutic Corporation (US) 2006-06-21 EP disclosed
US-20050113340-A1 2-Aminopurine analogs having HSP90-inhibiting activity CONFORMA THERAPEUTICS CORPORATION 2005-05-26 US disclosed
WO-2005028434-A2 NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS CONFORMA THERAPEUTICS CORPORATION (US) 2005-03-31 WO disclosed
US-5922889-A REACTING 3,7-DIMETHYL-6,8-DIMETHOXYISOCHROMAN WITH SODIUM ETHYL THIOLATE OR SODIUM HYDRIDE TO PRODUCE 3,7-DIMETHYL-6-HYDROXY-8-METHOXYISOCHROMAN; POSSESS PHYTOTOXIC ACTIVITY USED AS A BIODEGRADABLE HERBICIDE THE UNITED STATES OD AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) 1999-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113340-A1 2-Aminopurine analogs having HSP90-inhibiting activity HSP90AB2P, HSP90AB1, HSP90AA1 CA2 4096/4885PTGS2 378/4885MEN1 4060/4885
US-20070185064-A1 2-Aminopurine Analogs Having HSP90-Inhibiting Activity HSP90AB2P, HSP90AB1, HSP90AA1 CA2 4096/4885PTGS2 378/4885MEN1 4060/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.